drugset / Trial / NCT01532336

Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis

NCT01532336 ↗

Phase 2 Completed 500 enrolled NovaBay Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis. Adults and children one year of age and older with diagnosis of adenoviral conjunctivitis in at least one eye based upon a positive adenovirus test result using the Aden-Detactor Plus kit (Rapid Pathogen Screening, Inc). Subjects will be randomly assigned to receive either NVC-422 or Vehicle.

Timeline

Start
2012-05
Primary completion
2014-05
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject NVC-422 Unknown 0.3 % Other

Indications